Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Baxter
AstraZeneca
Boehringer Ingelheim
Moodys

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FENOFIBRATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Fenofibrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000620 ↗ Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed Centers for Disease Control and Prevention Phase 3 1999-09-01 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗ Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Eye Institute (NEI) Phase 3 1999-09-01 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗ Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 1999-09-01 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗ Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Institute on Aging (NIA) Phase 3 1999-09-01 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗ Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1999-09-01 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fenofibrate

Condition Name

Condition Name for Fenofibrate
Intervention Trials
Dyslipidemia 23
Hypertriglyceridemia 19
Hyperlipidemia 15
Hypercholesterolemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fenofibrate
Intervention Trials
Dyslipidemias 43
Hyperlipidemias 28
Hypertriglyceridemia 25
Hyperlipoproteinemias 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fenofibrate

Trials by Country

Trials by Country for Fenofibrate
Location Trials
United States 433
Canada 26
Germany 23
France 15
Korea, Republic of 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fenofibrate
Location Trials
Florida 25
Texas 23
California 23
Illinois 20
Tennessee 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fenofibrate

Clinical Trial Phase

Clinical Trial Phase for Fenofibrate
Clinical Trial Phase Trials
Phase 4 34
Phase 3 42
Phase 2/Phase 3 8
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fenofibrate
Clinical Trial Phase Trials
Completed 116
Terminated 17
Unknown status 15
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fenofibrate

Sponsor Name

Sponsor Name for Fenofibrate
Sponsor Trials
Solvay Pharmaceuticals 17
Abbott 10
Merck Sharp & Dohme Corp. 8
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fenofibrate
Sponsor Trials
Other 122
Industry 108
NIH 26
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Boehringer Ingelheim
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.